We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ulcerative colitis

News List

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data biospace
March 14, 2018
Protalix Biotherapeutics, Inc. believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.
US panel backs Pfizer’s Xeljanz for ulcerative colitis pharmatimes
March 12, 2018
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis pharmaceutical-technology
July 18, 2017
The US Food and Drug Administration (FDA) has accepted for filing Pfizer’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult patients affected with moderately to severely active ulc